Former FDA deputies land at big pharma Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 23 January, 2026

#JPM26 Spotlights. Excellent Human-Monkey Cross-Reactivity. This CD3-VHH Potently Accelerates the Clinical Translation of TCE Drugs sponsored by Fapon Biopharma

presented by A Psy­che­del­ic Re­nais­sance: How Defini­um Ther­a­peu­tics is Chang­ing How We Think about LSD and Treat Men­tal Health

news Lilly was the only pharma bidder for Ventyx Insurance CEOs defend their businesses at House hearing Peer Review Former FDA deputies land at Lilly, AbbVie; Italy's Angelini has a new CEO

Catch up on all the sessions from Endpoints at #JPM26, including conversations with Novo Nordisk CEO Mike Doustdar and Nobel laureate Fred Ramsdell on where biopharma is heading next. Visit our on-demand hub to watch now.

ENDPOINTS PHARMA High court picked Hikma’s ‘skinny label’ fight after letting the issue ‘percolate’  Top drugmakers spent slightly less on Washington lobbying in 2025's final quarter Roche boosts NC factory investment to $2B; Rentschler CEO steps down

Analyst – Life Sciences Strategy & Intelligence Sedulo Group Remote Vice President, Investor Relations & Communications C4 Therapeutics Watertown, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

in case you missed it 1. Amicus reveals it had another suitor before reaching $4.8B sale to BioMarin 2. BioMarin vets spearhead new biotech with $82M for rare disease drugs 3. Bristol Myers signs deal with Janux on T cell engager for $50M upfront 4. China-rooted Corxel raises up to $287M for GLP-1 pill with global ambitions 5. News Briefing A trio of biotechs targets $500M+ offerings 6. Corcept's drug extends patients' lives in key ovarian cancer study 7. Hua Medicine plots diabetes drug expansion in China and beyond 8. Moderna Is Curbing Investment in Vaccine Trials Due to US Backlash 9. Trump Administration Cuts Off Funding for Fetal Tissue Research. Again.